Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06762808
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Given by IV infusion
  • Talazoparib — DRUG
    Given by IV infusion

Study Details

A single-arm, phase II study for patients with detectable HPV CtDNA at 12 weeks or longer after completion of definitive therapy for non-metastatic, HPV+ squamous cell carcinoma.

Key Dates

First listed
Jan 8, 2025
Start date
May 1, 2025
Status verified
Aug 2025
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab + Tiragolumab
    Treatment will be administered on an outpatient basis

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Find similar trials

Nationwide
Skin cancer trialsOncology trialsSkin cancer trialsDermatology trials

Related Studies